Lyell Immunopharma, Inc. Other Operating Income (Expense), Net
Lyell Immunopharma, Inc. (LYEL) reported Other Operating Income (Expense), Net of $1.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherOperatingIncomeExpenseNet · last filed 2026-08-06
- Lyell Immunopharma, Inc. other operating income (expense), net for the quarter ending 2026-06-30 was $1.76M.
- Lyell Immunopharma, Inc. other operating income (expense), net for the quarter ending 2026-03-31 was $1.90M, a 1493.28% increase year-over-year.
- Lyell Immunopharma, Inc. other operating income (expense), net for the quarter ending 2025-12-31 was $1.50M, a 191.81% increase year-over-year.
- Lyell Immunopharma, Inc. other operating income (expense), net for the quarter ending 2025-09-30 was $1.59M, a 117.95% increase year-over-year.
- Lyell Immunopharma, Inc. other operating income (expense), net for fiscal 2025 was $2.15M, a 35.18% decline from fiscal 2024.
- Lyell Immunopharma, Inc. other operating income (expense), net for fiscal 2024 was $3.31M, a 18.60% increase from fiscal 2023.
- Lyell Immunopharma, Inc. other operating income (expense), net for fiscal 2023 was $2.79M, a 41.31% decline from fiscal 2022.
- Lyell Immunopharma, Inc. other operating income (expense), net for fiscal 2022 was $4.75M, a 104.56% increase from fiscal 2021.
| Period end | Other Operating Income (Expense), Net 3 month | Other Operating Income (Expense), Net 6 month | Other Operating Income (Expense), Net 9 month | Other Operating Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.76M 10-Q · filed 2026-08-06 | $3.65M 10-Q · filed 2026-08-06 | $5.15M derived: sum of 3 quarters · filed 2026-08-06 | $6.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.90M 10-Q · filed 2026-05-06 | $3.39M derived: sum of 2 quarters · filed 2026-05-06 | $4.98M derived: sum of 3 quarters · filed 2026-05-06 | $3.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.09M derived: sum of 2 quarters · filed 2026-03-12 | $2.03M derived: sum of 3 quarters · filed 2026-08-06 | $2.15M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.59M 10-Q · filed 2025-11-12 | $529.00K derived: sum of 2 quarters · filed 2026-08-06 | $648.00K 10-Q · filed 2025-11-12 | $1.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.06M 10-Q · filed 2026-08-06 | -$943.00K 10-Q · filed 2026-08-06 | -$430.00K derived: sum of 3 quarters · filed 2026-08-06 | $300.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $119.00K 10-Q · filed 2026-05-06 | $632.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.36M derived: sum of 3 quarters · filed 2026-05-06 | $2.34M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $513.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.24M derived: sum of 2 quarters · filed 2026-03-12 | $2.22M derived: sum of 3 quarters · filed 2026-03-12 | $3.31M 10-K · filed 2026-03-12 |
| 2024-09-30 | $730.00K 10-Q · filed 2025-11-12 | $1.71M derived: sum of 2 quarters · filed 2025-11-12 | $2.80M 10-Q · filed 2025-11-12 | $3.44M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $976.00K 10-Q · filed 2025-08-12 | $2.07M 10-Q · filed 2025-08-12 | $2.71M derived: sum of 3 quarters · filed 2026-03-12 | $3.00M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $1.09M 10-Q · filed 2025-05-13 | $1.73M derived: sum of 2 quarters · filed 2026-03-12 | $2.02M derived: sum of 3 quarters · filed 2026-03-12 | $2.59M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $641.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $933.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.50M derived: sum of 3 quarters · filed 2026-03-12 | $2.79M 10-K · filed 2026-03-12 |
| 2023-09-30 | $292.00K 10-Q · filed 2024-11-07 | $861.00K derived: sum of 2 quarters · filed 2024-11-07 | $2.15M 10-Q · filed 2024-11-07 | $3.36M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $569.00K 10-Q · filed 2024-08-07 | $1.86M 10-Q · filed 2024-08-07 | $3.07M derived: sum of 3 quarters · filed 2025-03-11 | $4.32M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $1.29M 10-Q · filed 2024-05-06 | $2.50M derived: sum of 2 quarters · filed 2025-03-11 | $3.75M derived: sum of 3 quarters · filed 2025-03-11 | $4.92M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $2.46M derived: sum of 2 quarters · filed 2025-03-11 | $3.63M derived: sum of 3 quarters · filed 2025-03-11 | $4.75M 10-K · filed 2025-03-11 |
| 2022-09-30 | $1.25M 10-Q · filed 2023-11-07 | $2.42M derived: sum of 2 quarters · filed 2023-11-07 | $3.54M 10-Q · filed 2023-11-07 | $4.34M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $1.17M 10-Q · filed 2023-08-08 | $2.29M 10-Q · filed 2023-08-08 | $3.09M derived: sum of 3 quarters · filed 2024-02-28 | $3.85M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.12M 10-Q · filed 2023-05-04 | $1.92M derived: sum of 2 quarters · filed 2024-02-28 | $2.68M derived: sum of 3 quarters · filed 2024-02-28 | $2.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $798.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.56M derived: sum of 2 quarters · filed 2024-02-28 | $1.78M derived: sum of 3 quarters · filed 2024-02-28 | $2.32M 10-K · filed 2024-02-28 |
| 2021-09-30 | $758.00K 10-Q · filed 2022-11-08 | $981.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.53M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $223.00K 10-Q · filed 2022-08-04 | $768.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $545.00K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $9.43M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |